Trulive Completes New Round of Over 100 Million Yuan Series C Financing, Continuing to Strengthen Platform Layout in Cardiovascular Intervention

Trulive officially announced the completion of its Series C financing of hundreds of millions of yuan, jointly invested by Oriental Fortune Capital, Guoyuan Equity, Xiamen Industrial Investment/Venture Capital, and other institutions.

Trulive officially announced the completion of its Series C financing of hundreds of millions of yuan, jointly invested by Oriental Fortune Capital, Guoyuan Equity, Xiamen Industrial Investment/Venture Capital, and other institutions.

Related Articles

You might also be interested in these

Trulive Medical Launches NeoBlazar® Transcatheter Edge-to-Edge Repair System, Marking the New Domestic Era for Tricuspid Interventional Therapy

Trulive Medical Launches NeoBlazar® Transcatheter Edge-to-Edge Repair System, Marking the New Domestic Era for Tricuspid Interventional Therapy

7/22/2026

Double List Honors! Trulive Medical Named to Future Healthcare 100 List Again, Dual Rankings Demonstrate Solid Innovation Capabilities

Double List Honors! Trulive Medical Named to Future Healthcare 100 List Again, Dual Rankings Demonstrate Solid Innovation Capabilities

5/22/2026

Trulive Medical's Self-Developed PAFLASH® Pulmonary Thrombus Removal System Obtains NMPA Approval for Market Launch

Trulive Medical's Self-Developed PAFLASH® Pulmonary Thrombus Removal System Obtains NMPA Approval for Market Launch

3/26/2026